RxDoctor Payments Data

Merrill Krolick, DO

Interventional Cardiology · Largo, FLNPI 1417919499

Payments from drug & device makers

$207,758in general payments, 2019–2025

Across 1,307 payments — averaging $158.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merit Medical Systems Inc$35K
  • Cardiovascular Systems Inc.$27K
  • Shockwave Medical, Inc$27K
  • Abbott$26K
  • Medtronic$22K
  • M.a. Med Alliance S.A.$17K
  • plus $54K from 54 others

What the payments were for

  • Royalty or licence$30,30518%
  • Consulting fees$26,89616%
  • Speaking & faculty fees$53,36931%
  • Travel & lodging$13,9348%
  • Food & beverage$39,92123%
  • Education$3,7202%
  • Gifts$830%
  • Ownership interest$4,2132%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merit Medical Systems Inc27$34,517
Cardiovascular Systems Inc.216$26,991
Shockwave Medical, Inc232$26,835
Abbott138$26,287
Medtronic(2 entities)135$22,197
M.a. Med Alliance S.A.8$17,412
Penumbra, Inc.65$16,542
AstraZeneca21$9,927
Medalliance LLC6$6,130
Cordis US CORP.29$3,485
EKOS Corporation3$1,923
Boston Scientific45$1,795
Acist Medical Systems, Inc.40$1,463
Abiomed32$1,129
Endologix LLC17$1,085
Bolton Medical Inc16$964
W. L. Gore & Associates, Inc.9$882
Medicure Pharma Inc.3$774
Inari Medical, Inc.19$734
Johnson & Johnson33$631
Terumo Medical Corporation4$626
Angiodynamics, Inc.8$607
Pfizer34$576
Bard Peripheral Vascular, Inc.6$568
Amgen29$463
Philips North America LLC5$435
Novartis17$271
Novo Nordisk11$222
Merck11$210
Sanofi-aventis U.S. LLC12$209
Stryker3$187
E.r. Squibb & Sons, L.L.C.13$180
Chiesi USA, Inc.6$160
Reflow Medical Inc1$136
Osprey Medical Inc1$127
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)8$124
Esperion Therapeutics, Inc.6$112
Kestra Medical Technology Services, Inc.4$101
Cardiva Medical, Inc.2$82
Boehringer Ingelheim4$71
Actelion Pharmaceuticals US, Inc.3$56
Amarin Pharma, Inc.3$54
Cardinal Health 200 LLC1$51
Siemens Medical Solutions USA, Inc.1$44
Alnylam Pharmaceuticals Inc.1$39
Bayer2$37
Lexicon Pharmaceuticals, Inc.2$28
Kowa Pharmaceuticals America, Inc.2$28
Recor Medical Inc1$25
Astellas Pharma US Inc1$23
Preventice Services, LLC1$22
United Therapeutics Corporation1$22
Scpharmaceuticals Inc.1$22
Biosense Webster, Inc.1$22
Regeneron Healthcare Solutions, Inc.1$21
Lilly USA, LLC1$18
Kiniksa Pharmaceuticals International, PLC1$17
Atricure, Inc.1$15
Baxter Healthcare1$14
Arbor Pharmaceuticals, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$207,758 in reported general payments places this provider in the 85th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$308,460
Medicare patients
780
Services billed
2,853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban125$149,804
XareltoRivaroxaban88$112,669
EntrestoSacubitril/Valsartan28$37,633
FarxigaDapagliflozin Propanediol25$29,188
JardianceEmpagliflozin13$13,431
Ranolazine ErRanolazine26$1,823
ClopidogrelClopidogrel Bisulfate135$1,456
Metoprolol Succinate121$1,424
Atorvastatin Calcium136$1,145
Bumetanide11$1,035
Ezetimibe34$787
Rosuvastatin Calcium62$778
Propafenone Hcl17$772
Nebivolol Hcl14$648
Amlodipine Besylate110$615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$576$149,804125 claims
Johnson & JohnsonXarelto$631$112,66988 claims
NovartisEntresto$271$37,63328 claims
AstraZenecaFarxiga$9,927$29,18825 claims
Boehringer IngelheimJardiance$71$13,43113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Largo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →